13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001703031
Total reported value
$1.7B
$1.7B
19 檔
60.4%
In Q4 2025, Bain Capital Life Sciences Investors, LLC's U.S. equity holdings reached a combined market value of $1.7B, distributed across 19 disclosed stock positions.
In Q4 2025, Bain Capital Life Sciences Investors, LLC adopted a defensive or profit-taking posture, trimming 7 positions and completely liquidating 2 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | HTFL | Heartflow Inc | Stock-Other | 27.79% | -8.19% | — | |
| 2 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 19.63% | -13.42% | -31.84% | |
| 3 | OLMA | Olema Pharmaceuticals Inc | Stock-Other | 16.29% | -4.78% | +24.32% | |
| 4 | SVRA | Savara Inc | Stock-Other | 8.13% | -2.22% | — | |
| 5 | PHVS | Pharvaris N.V. | Stock-Other | 5.96% | -1.32% | -11.92% | |
| 6 | SLDB | Solid Biosciences Inc | Stock-Other | 3.42% | -0.54% | — | |
| 7 | UPB | Upstream Bio Inc | Stock-Other | 2.76% | -0.45% | -45.50% | |
| 8 | XFOR | X4 Pharmaceuticals Inc | Stock-Other | 2.44% | -0.76% | +226.99% | |
| 9 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 2.35% | -0.64% | -43.49% | |
| 10 | KYTX | Kyverna Therapeutics Inc | Stock-Other | 2.24% | -0.89% | -7.67% | |
| 11 | ANNX | Annexon Inc | Stock-Other | 2.02% | -1.09% | — | |
| 12 | RPID | Rapid Micro Biosystems Inc-a | Stock-Other | 1.87% | -0.86% | — | |
| 13 | CABA | Cabaletta Bio Inc | Stock-Other | 1.62% | +0.84% | — | |
| 14 | CCCC | C4 Therapeutics Inc | Stock-Other | 1.05% | +0.29% | +545.01% | |
| 15 | MRSN | Mersana Therapeutics Inc | Stock-Other | 0.77% | — | — | |
| 16 | AVIR | Atea Pharmaceuticals Inc | Stock-Other | 0.68% | -0.58% | — | |
| 17 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.44% | — | -75.90% | |
| 18 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.36% | — | +61.44% | |
| 19 | ✓ | Newamsterdam Pharma Company | Stock-Other | 0.18% | -0.05% | -0.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | OLMA | Olema Pharmaceuticals Inc | +11.8% | +24.32% | Add |
| 2 | SVRA | Savara Inc | +4% | — | Unchanged |
| 3 | XFOR | X4 Pharmaceuticals Inc | +1.9% | +226.99% | Add |
| 4 | ANNX | Annexon Inc | +1% | — | Unchanged |
| 5 | KYTX | Kyverna Therapeutics Inc | +0.9% | -7.67% | Trim |
| 6 | CCCC | C4 Therapeutics Inc | +0.9% | +545.01% | Add |
| 7 | PHVS | Pharvaris N.V. | +0.7% | -11.92% | Trim |
| 8 | MRSN | Mersana Therapeutics Inc | +0.6% | — | Unchanged |
| 9 | AVIR | Atea Pharmaceuticals Inc | +0.2% | — | Unchanged |
| 10 | SLDB | Solid Biosciences Inc | +0.2% | — | Unchanged |
| 11 | CABA | Cabaletta Bio Inc | +0.1% | — | Unchanged |
| 12 | ✓ | Xilio Therapeutics Inc | +0.1% | +61.44% | Add |
| 13 | ✓ | Newamsterdam Pharma Company | +0.1% | -0.00% | Trim |
| 14 | RPID | Rapid Micro Biosystems Inc-a | — | — | Unchanged |
| 15 | HTFL | Heartflow Inc | 0% | — | Unchanged |
| 16 | UPB | Upstream Bio Inc | -0.3% | -45.50% | Trim |
| 17 | NAMS | NewAmsterdam Pharma Company N.V. | -0.6% | -31.84% | Trim |
| 18 | TNGX | Tango Therapeutics Inc | -1.1% | -75.90% | Trim |
| 19 | DNTH | Dianthus Therapeutics Inc | -1.1% | -43.49% | Trim |
| 20 | CDTX | Cidara Therapeutics Inc | — | EXIT | Sold out |
| 21 | IPSC | Century Therapeutics Inc | — | EXIT | Sold out |
According to official SEC Form 13F filings, Bain Capital Life Sciences Investors, LLC reported a total U.S. public equity portfolio value of $1.7B across 19 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including HTFL, NAMS, OLMA) accounted for 60.4% of total reported equity market value during Q4 2025.
Top Position Liquidated / Trimmed
CDTX
前期市值: $289.3M
During Q4 2025, Bain Capital Life Sciences Investors, LLC's top holdings by market value included HTFL (27.8%)、NAMS (19.6%)、OLMA (16.3%). The largest single position, HTFL, represented 27.8% of total portfolio value.
In Q4 2025, Bain Capital Life Sciences Investors, LLC made 13 total portfolio adjustments, initiating 0 new buys, adding to 4 positions, trimming 7 holdings, and fully liquidating 2 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.